Differences in drug therapy between dementia disorders in the swedish dementia registry: A nationwide study of over 7,000 patients

Dementia and Geriatric Cognitive Disorders

Volumn 35, Issue 5-6, 2013, Pages 239-248

  Johnell, Kristina ^a   Religa, Dorota ^b,d   Eriksdotter, Maria ^c,d  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b Department of Neurobiology   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Dementia; Drug treatment; Swedish Dementia Registry

Indexed keywords

CHOLINESTERASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; DEMENTIA; DEMOGRAPHY; DIFFUSE LEWY BODY DISEASE; DRUG USE; FEMALE; HUMAN; INSTITUTIONALIZATION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; RESIDENTIAL AREA; SEX; VERY ELDERLY;

EID: 84874807147     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000348408     Document Type: Article

References (46)

1. Brunnstrom H, Gustafson L, Passant U, Englund E: Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr 2009; 49: 146-149.
2. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R: Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003; 74:720-724.
3. Zaccai J, McCracken C, Brayne C: A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34: 561-566.
4. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
5. Alladi S, Mekala S, Chadalawada SK, Jala S, Mridula R, Kaul S: Subtypes of dementia: a study from a memory clinic in India. Dement Geriatr Cogn Disord 2011; 32: 32-38.
6. Religa D, Winblad B: Therapeutic strategies for Alzheimer's disease based on new molecular mechanisms. Acta Neurobiol Exp (Wars) 2003; 63: 393-396.
7. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Ryden M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L: Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-160.
8. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D: Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16: 653-666.
9. Forstl H, Stamouli SS, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M: Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord 2011; 32: 267-272.
10. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63: 49-54.
11. National Board of Health and Welfare: Nationella riktlinjer för vård och omsorg vid demenssjukdom 2010. Stockholm, Socialstyrelsen, 2010.
12. Aarsland D, Mosimann UP, McKeith IG: Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17: 164-171.
13. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000; 15: 794-802.
14. Mori E, Ikeda M, Kosaka K: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72: 41-52.
15. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
16. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
17. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613-618.
18. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Blad-strom A, Jones R: Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977.
19. Swedish Medical Products Agency: Treatment of behavioral and psychological symptoms of dementia (BPSD) (in Swedish). Swedish Medical Products Agency 2008: 5.
20. Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M, Sykora K, Lipscombe L, Bell CM, Gurwitz JH: Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168: 1090-1096.
21. Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, Bisanti L: Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 31: 218-224.
22. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS: Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168: 831-839.
23. Corbett A, Smith J, Creese B, Ballard C: Treatment of behavioral and psychological symptoms of Alzheimer's disease. Curr Treat Options Neurol 2012; 14: 113-125.
24. Laitinen ML, Bell JS, Lavikainen P, Lonnroos E, Sulkava R, Hartikainen S: Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. Int Psychogeriatr 2011; 23: 1623-1631.
25. Lovheim H, Sandman PO, Kallin K, Karlsson S, Gustafson Y: Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr 2006;18:713-726.
26. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
27. Religa D, Spångberg K, Wimo A, Edlund AK, Winblad B, Eriksdotter-Jönhagen M: Dementia diagnosis differs in men and women and depends on age and dementia severity: data from SveDem, the Swedish Dementia Quality Registry. Dement Geriatr Cogn Disord 2012; 33: 90-95.
28. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.
29. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994; 57: 416-418.
30. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ: Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-864.
31. Fratiglioni L, De Ronchi D, Aguero-Torres H: Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15: 365-375.
32. Alladi S, Mekala S, Chadalawada SK, Jala S, Mridula R, Kaul S: Subtypes of dementia: a study from a memory clinic in India. Dement Geriatr Cogn Disord 2011; 32: 32-38.
33. Rosso SM, Donker Kaat L, Baks T, Joosse M, de Koning I, Pijnenburg Y, de Jong D, Dooijes D, Kamphorst W, Ravid R, Niermeijer MF, Verheij F, Kremer HP, Scheltens P, van Duijn CM, Heutink P, van Swieten JC: Fronto-temporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003; 126: 2016-2022.
34. Ratnavalli E, Brayne C, Dawson K, Hodges JR: The prevalence of frontotemporal dementia. Neurology 2002; 58: 1615-1621.
35. Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L: An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Alzheimers Dement 2012; 8: 22-30.
36. Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B, REAL.FR Study Group: Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement 2011; 7: 579-592.
37. Epstein NU, Saykin AJ, Risacher SL, Gao S, Farlow MR: Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. Drugs Aging 2010; 27: 677-686.
38. Johnell K, Ringbäck Weitoft G, Fastbom J: Education and use of dementia drugs: a register-based study of over 600, 000 older people. Dement Geriatr Cogn Disord 2008; 25: 54-59.
39. Sinforiani E, Citterio A, Zucchella C, Bono G, Corbetta S, Merlo P, Mauri M: Impact of gender differences on the outcome of Alzheimer's disease. Dement Geriatr Cogn Disord 2010; 30: 147-154.
40. Schneider LS, Dagerman KS, Higgins JP, McShane R: Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; 68: 991-998.
41. Calvo-Perxas L, Lopez-Pousa S, Vilalta-Franch J, Turro-Garriga O, Blankenburg M, Febrer L, Flaque M, Vallmajo N, Aguirregomozcorta M, Genis D, Casas I, Perkal H, Coromina J, Garre-Olmo J: Central nervous system drug consumption depending on the time between symptom onset and the diagnosis of Alzheimer's disease: an analysis by the Registry of Dementias of Girona. Dement Geriatr Cogn Disord 2012; 33: 104-110.
42. Johnell K, Fastbom J: Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden. Drugs Aging 2012; 29: 751-758.
43. Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S: Variation in anti-psychotic treatment choice across US nursing homes. J Clin Psychopharmacol 2012; 32: 11-17.
44. Bjoerke-Bertheussen J, Ehrt U, Rongve A, Ballard C, Aarsland D: Neuropsychiatric symptoms in mild dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 34: 1-6.
45. Ballard C, Kahn Z, Corbett A: Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs Aging 2011; 28: 769-777.
46. SveDem annual report 2010 (in Swedish). 2011. http://www.ucr.uu.se/svedem/index.php/arsrapporter.